Editas Medicine

Why Editas Medicine Stock Is Tumbling Today
Why Editas Medicine Stock Is Tumbling Today
Motley Fool
Editas Medicine
JPMHC 2021
EDIT-301
EDIT-101
Flag link:
AbbVie cuts Editas CRISPR pact it inherited from Allergan
AbbVie cuts Editas CRISPR pact it inherited from Allergan
Fierce Biotech
Editas Medicine
Allergan
AbbVie
gene editing
CRISPR
Flag link:
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia
earnings
Flag link:
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Flag link:
Here's Why CRISPR Stocks Fell in January
Here's Why CRISPR Stocks Fell in January
Motley Fool
Intellia Therapeutics
CRISPR Therapeutics
Editas Medicine
CRISPR
Flag link:
Overview: CRISPR Technology Headed to Clinical Trials
Overview: CRISPR Technology Headed to Clinical Trials
BioSpace
CRISPR
Editas Medicine
clinical trials
Allergan
LCA10
Flag link:
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Celgene Gave This Tech Back to Editas Medicine, but It Could Prove Valuable
Motley Fool
Celgene
Editas Medicine
Juno Therapeutics
CRISPR
gene editing
Flag link:
More CRISPR Stock Catalysts Ahead
More CRISPR Stock Catalysts Ahead
Motley Fool
gene editing
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Flag link:
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Editas and Celgene sub Juno are tackling hottest immunotherapy cells
Endpoints
Editas Medicine
Celgene
Juno Therapeutics
CRISPR
gene editing
immunotherapy
Flag link:
Editas Medicine Appoints Cynthia Collins President & CEO
Editas Medicine Appoints Cynthia Collins President & CEO
Xconomy
Editas Medicine
Flag link:
Editas, Allergan launch first in vivo study of CRISPR-based medicine
Editas, Allergan launch first in vivo study of CRISPR-based medicine
BioPharma Dive
Editas Medicine
Allergan
clinical trials
CRISPR
EDIT-101
Flag link:
Should Sangamo's Failure Make CRISPR Investors Nervous?
Should Sangamo's Failure Make CRISPR Investors Nervous?
Motley Fool
Sangamo Therapeutics
gene editing
CRISPR
CRISPR Therapeutics
Editas Medicine
Flag link:
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
Xconomy
Editas Medicine
Katrine Bosley
CRISPR
Flag link:
FDA signs off on Editas CRISPR study on patients with a rare genetic disorder
FDA signs off on Editas CRISPR study on patients with a rare genetic disorder
Stat
CRISPR
Editas Medicine
FDA
Flag link:
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
Motley Fool
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Flag link:
Allergan and Editas exercise CRISPR option
Allergan and Editas exercise CRISPR option
Biopharma Dive
Allergan
Editas Medicine
CRISPR
EDIT-101
gene editing
Flag link:
Here's Why CRISPR Stocks Are Down as Much as 11.4% Today
Here's Why CRISPR Stocks Are Down as Much as 11.4% Today
Motley Fool
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Flag link:
CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic
CRISPR Could Cause Cancer? Here Are 3 Reasons Investors Shouldn't Panic
Motley Fool
CRISPR
CRISPR Therapeutics
Editas Medicine
Intellia Therapeutics
Flag link:
Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May
Here's Why the Top CRISPR Stocks Rose as Much as 47.1% in May
Motley Fool
CRISPR
Editas Medicine
Intellia Therapeutics
CRISPR Therapeutics
Flag link:
Editas Medicine Starts a "Transformative" Year on a High Note
Editas Medicine Starts a "Transformative" Year on a High Note
Motley Fool
Editas Medicine
earnings
CRISPR
Flag link:

Pages